(Q44908820)

7 December 2017

title

Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effect on vaccine efficacy (English)

1 reference

7 December 2017

1

1 reference

7 December 2017

8

Jamie F S Mann

1 reference

7 December 2017

Rosaria Costa

2

1 reference

7 December 2017

K Christine Carter

3

1 reference

7 December 2017

Michael J A Harvey

4

1 reference

7 December 2017

Mary M Waterston

5

1 reference

7 December 2017

Alexander B Mullen

6

1 reference

7 December 2017

Christian Matschke

7

1 reference

7 December 2017

Angela Colston

9

1 reference

7 December 2017

William H Stimson

10

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

22

1 reference

7 December 2017

issue

8

1 reference

7 December 2017

page(s)

1024-1031

1 reference

Current advances in antifertility vaccines for fertility control and noncontraceptive applications.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Active immunization against gonadotrophin-releasing hormone in Chinese male pigs: effects of dose on antibody titer, hormone levels and sexual development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Gonadal function, sexual behavior, feedlot performance, and carcass traits of ram lambs actively immunized against GnRH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Anti-gonadotropin releasing hormone vaccines and their potential use in the treatment of hormone-responsive cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Immunization against GnRH in male species (comparative aspects).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Adjuvants for human vaccines--current status, problems and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Comparison of conventional adjuvants and 'adjuvant-free' monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinizing hormone releasing hormone and avidin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

An investigation into the immunogenicity of a GnRH analogue in male rats: a comparison of the toxicity of various adjuvants used in conjunction with GnRH-glycys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Sustained-release injectables formed in situ and their potential use for veterinary products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Influence of carrier protein conjugation site and terminal modification of a GnRH-I peptide sequence in the development of a highly specific anti-fertility vaccine. Part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Part II: influence of dimerization of a modified GnRH-I peptide sequence on a male antifertility vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Immunoneutralisation of GnRH-I, without cross-reactivity to GnRH-II, in the development of a highly specific anti-fertility vaccine for clinical and veterinary use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Performance of male pigs immunized against GnRH is related to the time of onset of biological response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Modulation of antigen-specific T and B cell responses influence bacterial clearance of non-typeable Haemophilus influenzae from the lung in a rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Immunoglobulin subclass responses of wild brown rats to Sarcocystis singaporensis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Aluminum compounds used as adjuvants in vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.043

10.1016/J.VACCINE.2003.08.043

7 January 2021

Identifiers

DOI

1 reference

7 December 2017

1 reference